Adding a monoclonal antibody (MAb)-bevacizumab-to combination chemotherapy may increase survival in patients with recurrent cervical cancer, according to results of a National Cancer Institute-funded randomized trial. Use of bevacizumab in cervical cancer is experimental; the MAb currently is approved to treat metastatic colorectal cancer, non-squamous, non-small cell lung cancer, and glioblastoma.
Adding a monoclonal antibody (MAb)-bevacizumab-to combination chemotherapy may increase survival in patients with recurrent cervical cancer, according to results of a National Cancer Institute-funded randomized trial. Use of bevacizumab in cervical cancer is experimental; the MAb currently is approved to treat metastatic colorectal cancer, non-squamous, non-small cell lung cancer, and glioblastoma.
Published in the New England Journal of Medicine, the study evaluated the effectiveness of bevacizumab and nonplatinum combination chemotherapy in 452 patients with recurrent, persistent, or metastatic cervical cancer. Chemotherapy consisted of cisplatin (50 mg/m2) plus paclitaxel (135 or 175 mg/m2) or topotecan (0.75 mg/m2) on days 1 to 3, plus paclitaxel (175 mg/m2) on day 1. The bevacizumab dosage was 15 mg/kg of body weight. Randomization was to treatment with and without the addition of the MAb and cycles were repeated every 21 days until disease progressed, patients developed unacceptable toxic effects, or a complete response was documented.
Overall survival was the primary endpoint and a 30% reduction in the hazard ratio for death was considered clinically important. In patients who received chemotherapy plus bevacizumab, overall survival was 17.0 months versus 13.3 months in those who received chemotherapy alone (hazard ratio for death 0.71; 98% confidence interval, 0.54 to 0.95; P=0.004). Response rates also were higher with the MAb (48% vs 36%; P=0.008). Bevacizumab was associated with increased incidence of hypertension of grade 2 or higher (25% vs 2%) thromboembolic events of grade 3 or higher (8% vs 1%) and gastrointestinal fistulas of grade 3 or higher (3% vs 0%).
To get weekly advice for today's Ob/Gyn, subscribe to the Contemporary Ob/Gyn Special Delivery.
Dostarlimab shows significant survival benefits in endometrial cancer trial
March 21st 2024GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.
Read More
Unifying radical hysterectomy classifications with the Querleu-Morrow
February 16th 2024Explore how the latest research underscores the efficacy of the 2017 Querleu-Morrow classification in defining radical hysterectomy extent, shedding light on surgical terminologies for cervical cancer management.
Read More